Copyright 2006 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2006
Lupus erythematosus profundus (LEP) is a clinical subtype of cutaneous lupus erythematosus that has a chronic and recurrent clinical course. Systemic corticosteroids, which are often administered in cases of LEP complicated with systemic lupus erythematosus, are generally effective but cause side effects. Thus, other therapeutic options are needed. Hydroxychloroquine and thalidomide have occasionally been used as first-line therapies for LEP1,2; however, the sale of them is prohibited in Japan because of their severe side effects. Alternatively, dapsone has been used in Japan. Indeed, there were several case reports written in the Japanese literature describing patients with LEP successfully treated with dapsone; however, few cases have been reported in the English literature.3,4 Herein we report a case of LEP successfully treated with dapsone, and we review the previous Japanese cases.
Ujiie H, Shimizu T, Ito M, Arita K, Shimizu H. Lupus Erythematosus Profundus Successfully Treated With Dapsone: Review of the Literature. Arch Dermatol. 2006;142(3):393-403. doi:10.1001/archderm.142.3.399